Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055556 | 0.84 | GAA (0.71) | RAB9ANPC1MEN1KMT2AGAA | |
| SCHEMBL17661777 | 0.84 | RAB9A (0.68) | RAB9ANPC1MEN1KMT2AGAA | |
| SCHEMBL2486560 | 0.84 | RAB9A (0.68) | RAB9ANPC1MEN1KMT2AGAA | |
| SCHEMBL755893 | 0.81 | RAB9A (0.64) | RAB9ANPC1MEN1KMT2AGAA | |
| SCHEMBL2727856 | 0.80 | HDAC6 (0.73) | RAB9ANPC1GAAMAPTTP53 | |
| SCHEMBL14882044 | 0.80 | GAA (0.58) | RAB9ANPC1MEN1KMT2AGFER | |
| SCHEMBL9910545 | 0.79 | NPC1 (0.62) | RAB9ANPC1MEN1KMT2AGAA | |
| SCHEMBL2886105 | 0.79 | RAF1 (0.66) | RAB9ANPC1HDAC6 | |
| SCHEMBL13211387 | 0.78 | RAF1 (0.72) | RAB9ANPC1 | |
| SCHEMBL14881818 | 0.77 | TP53 (0.56) | RAB9ANPC1MEN1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013056679-A1 | NOVEL HETEROARYL-AMINO DERIVATIVES | BEIJING HANMI PHARMACEUTICAL CO., LTD (CN) | 2013-04-25 | — | — | WO | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20030236406-A1 | Method for the preparation of tetrahydrobenzothiepines | BABIAK KEVIN A (US) | 2003-12-25 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| EP-1042314-B1 | METHOD OF PREPARING ENANTIOMERICALLY-ENRICHED TETRAHYDROBENZOTHIEPINE OXIDES | SEARLE & CO (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236406-A1 | Method for the preparation of tetrahydrobenzothiepines | TMT1A, THOP1, BBOX1 | RAB9A 4560/4885NPC1 4587/4885MEN1 1818/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | RAB9A 975/4885NPC1 991/4885MEN1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.